Pharmacotherapy to Improve Outcomes in Infrainguinal Bypass Graft Surgery: A Review of Current Treatment Strategies

Annals of Vascular Surgery

Volumn 24, Issue 4, 2010, Pages 562-572

  Jackson, Andrew J ^a   Coats, Paul ^a   Orr, Douglas J ^a   Teenan, R Paul ^a   Wadsworth, Roger M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ECRAPROST; GUANOSINE TRIPHOSPHATASE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE DONOR; PLACEBO; PRASUGREL; PROSTAGLANDIN DERIVATIVE; RHO KINASE INHIBITOR; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY INTIMA PROLIFERATION; BLEEDING; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FOLLOW UP; GRAFT FAILURE; GRAFT OCCLUSION; GRAFT PATENCY; GRAFT SURVIVAL; HEART INFARCTION; HEMATOMA; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INFRAINGUINAL BYPASS GRAFT SURGERY; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VEIN GRAFT;

CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY; VASCULAR SURGICAL PROCEDURES; VEINS;

EID: 77951676467     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2010.02.028     Document Type: Review

References (65)

1. Ashley S., Ridler B., and Kinsman R. National Vascular Database Report. Vascular Surgical Society of Great Britain and Ireland National Vascular Database Report 2002 (2002), Dendrite Clinical Systems, Henley-on-Thames, United Kingdom
2. Lau H., and Cheng S.W. Long-term prognosis of femoropopliteal bypass: an analysis of 349 consecutive revascularizations. ANZJ. Surg. 71 (2001) 335-340
3. Norgren L. New international consensus document on peripheral arterial disease. TASC II for improved care. Lakartidningen 104 (2007) 1474-1475
4. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 321 (1989) 129-135
5. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 100 (2007) 1261-1275
6. Aktas B., Utz A., Hoenig-Liedl P., Walter U., and Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 34 (2003) 764-769
7. Storey R.F., Sanderson H.M., White A.E., May J.A., Cameron K.E., and Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br. J. Haematol. 110 (2000) 925-934
8. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 308 (1994) 159-168
9. Girolami B., Bernardi E., Prins M.H., ten Cate J.W., Prandoni P., Simioni P., et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur. J. Vasc. Endovasc. Surg. 19 (2000) 370-380
10. Tangelder M.J., Lawson J.A., Algra A., and Eikelboom B.C. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J. Vasc. Surg. 30 (1999) 701-709
11. Brown J., Lethaby A., Maxwell H., Wawrzyniak A.J., and Prins M.H. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Syst. Rev. (2008) CD000535
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
13. Cortelekoglu T., Bozkurt A.K., Ustundag N., Koksal C., and Sayin A.G. The effects of clopidogrel and calcium dobesilate on intimal hyperplasia following vascular injury. Acta Chir. Belg. 106 (2006) 206-210
14. Becquemin J.P. Effect of ticlopidine on the long term patency of saphenous-vein bypass grafts in the legs. N. Eng. J. Med. 337 (1997) 1726-1731
15. Dormandy J, Belch J. Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts: a Randomized Placebo Study. In: Abstract presented at VSS meeting 2007, 2007. Available at: http://www.vascularweb.org/Annual_Meeting/Abstracts/2007/dormandy_effect_adding_clopidogrel.html.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
17. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
18. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
19. Porter K.E., Naik J., Turner N.A., Dickinson T., Thompson M.M., and London N.J. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg. 36 (2002) 150-157
20. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33 (1999) 234-241
21. Ferro D., Basili S., Alessandri C., Cara D., and Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149 (2000) 111-116
22. Yamanouchi D., Banno H., Nakayama M., et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J. Vasc. Surg. 42 (2005) 757-764
23. Abbruzzese T.A., Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J. Vasc. Surg. 39 (2004) 1178-1185
24. Henke P.K., Blackburn S., Proctor M.C., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J. Vasc. Surg. 39 (2004) 357-365
25. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol. 49 (2007) 1272-1278
26. Anand S., Yusuf S., Xie C., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N. Engl. J. Med. 357 (2007) 217-227
27. The WAVE Investigators. The effects of oral anticoagulation in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am. Heart J. 151 (2006) 1-9
28. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomized trial. Lancet 355 (2000) 346-351
29. Sarac T.P., Huber T.S., Back M.R., et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J. Vasc. Surg. 28 (1998) 446-457
30. Johnson W.C., and Williford W.O. Benefits, morbidity, and mortality associated with long term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J. Vasc. Surg. 35 (2002) 413-421
31. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J. Renin. Angiotensin. Aldosterone Syst. 1 (2000) 18-20
32. Lam E.Y., Landry G.J., Edwards J.M., et al. Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts. J. Vasc. Surg. 39 (2004) 336-339
33. Sajgure A., Choudhury A., Ahmed Z., and Choudhury D. Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. Nephrol. Dial. Transplant 22 (2007) 1390-1398
34. Arosio E., Minuz P., Prior M., et al. Vascular adhesion molecule-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease. Life Sci. 69 (2001) 421-433
35. Salcedo R., Zhang X., Young H.A., et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
36. Smith F.C.T., Thomson I.A., Hickey N.C., et al. Adjuvant prostanoid treatment during femorodistal reconstruction. Ann. Vasc. Surg. 7 (1993) 88-94
37. The Iloprost Bypass International Study Group. Effects of perioperative iloprost on patency of femorodistal bypass grafts. Eur. J. Vasc. Surg. 12 (1996) 363-371
38. Nehler M.R., Brass E.P., Anthony R., et al. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J. Vasc. Surg. 45 (2007) 953-960
39. Barnett A.H., Bradbury A.W., Brittenden J., et al. The role of cilostazol in the treatment of intermittent claudication. Curr. Med. Res. Opin. 20 (2004) 1661-1670
40. Tsuchikane E., Fukuhara A., Kobayashi T., et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100 (1999) 21-26
41. Sekiguchi M., Hoshizaki H., Adachi H., et al. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ. J. 68 (2004) 610-614
42. Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler. Suppl. 6 (2005) 41-46
43. Iida O., Nanto S., Uematsu M., et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J. Vasc. Surg 48 (2008) 144-149
44. Hiroaki T., Hitoshi O., Nobuya Z., et al. Clinical usefulness of cilostazol in arteriosclerosis obliterans patients following infrainguinal bypass surgery. J. Jpn. Coll. Angiol. 43 (2003) 251-258
45. Varty K., Porter K., Bell P.R., and London N.J. Vein morphology and bypass graft stenosis. Br. J. Surg. 83 (1996) 1375-1379
46. Ahanchi S.S., Tsihlis N.D., and Kibbe M.R. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J. Vasc. Surg. 45 Suppl A (2007) A64-A73
47. Chen C., Mattar S.G., and Lumsden A.B. Oral administration of L-arginine reduces intimal hyperplasia in balloon-injured rat carotid arteries. J. Surg. Res. 82 (1999) 17-23
48. Groves P.H., Banning A.P., Penny W.J., et al. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc. Res. 30 (1995) 87-96
49. Lablanche J.M., Grollier G., Lusson J.R., et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Circulation 95 (1997) 83-89
50. Wohrle J., Hoher M., Nusser T., Hombach V., and Kochs M. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can. J. Cardiol. 19 (2003) 495-500
51. Rolland P.H., Mekkaoui C., Palassi M., et al. Efficacy of local molsidomine delivery from a hydrogel-coated angioplasty balloon catheter in the atherosclerotic porcine model. Cardiovasc. Intervent. Radiol. 26 (2003) 65-72
52. Zhan Y., Kim S., Izumi Y., et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 795-801
53. Dardik A., Yamashita A., Aziz F., Asada H., and Sumpio B.E. Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1alpha. J. Vasc. Surg. 41 (2005) 321-331
54. Gennaro G., Menard C., Michaud S.E., Deblois D., and Rivard A. Inhibition of vascular smooth muscle cell proliferation and neointimal formation in injured arteries by a novel, oral mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor. Circulation 110 (2004) 3367-3371
55. Ohashi N., Matsumori A., Furukawa Y., et al. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2521-2526
56. Pintucci G., Saunders P.C., Gulkarov I., et al. Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts. FASEB J. 20 (2006) 398-400
57. Davies M.G., Ramkumar V., Gettys T.W., and Hagen P.O. The expression and function of G-proteins in experimental intimal hyperplasia. J. Clin. Invest. 94 (1994) 1680-1689
58. Takai Y., Kaibuchi K., Kikuchi A., and Kawata M. Small GTP-binding proteins. Int. Rev. Cytol. 133 (1992) 187-230
59. Koch W.J., Hawes B.E., Allen L.F., and Lefkowitz R.J. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12706-12710
60. Porter K.E., and Turner N.A. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem. Soc. Trans. 30 (2002) 120-126
61. Work L.M., McPhaden A.R., Pyne N.J., et al. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 104 (2001) 1538-1543
62. Iso Y., Suzuki H., Sato T., et al. Rho-kinase inhibitor suppressed restenosis in porcine coronary balloon angioplasty. Int. J. Cardiol. 106 (2006) 103-110
63. Furuyama T., Komori K., Shimokawa H., et al. Long-term inhibition of Rho kinase suppresses intimal thickening in autologous vein grafts in rabbits. J. Vasc. Surg. 43 (2006) 1249-1256
64. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Eng. J. Med. 357 (2007) 2001-2015
65. Bhatt D.L. Prasugrel in clinical practice. N. Eng. J. Med. 361 (2009) 940-942